** Shares of India's Laurus Labs LAUL.NS down as much as
3.61% at 331.50 rupees
** Co "testing patience" of investors as core profit margins
sink to 19-qtr low - brokerage Kotak
** Weakness in core business over past 2 yrs certainly
unsettling - Kotak
** Adds all eyes on core Synthesis business after boost from
COVID-19 drug Paxlovid gone
** Rating house retains "reduce", but raises PT to 300
rupees from 285 rupees
** LAUL posted 90% slump in Q1 profit, rev slid 23%
** More than 7.9 mln shares changed hands by 2:16 p.m. IST,
3.7x 30-day avg
** Avg recommendation of 11 analysts "hold"; median PT 315
rupees - Refinitiv data
** Including session's losses, LAUL has fallen ~11% so far
(Reporting by Hritam Mukherjee in Bengaluru)
((Hritam.Mukherjee@thomsonreuters.com;))